Ollin – Talk Bio

Actionable Insights Powered by AI

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

Ollin Biosciences; Roche; eye disease; biotech; VEGF-A; Ang2; wet AMD; diabetic macular edema; clinical trial; OLN324; Vabysmo